Navigation Links
WaferGen Reports Second Quarter 2011 Financial Results
Date:9/12/2011

eport on Form 10-Q for the period ended March 31, 2011.  Security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov.  The company does not undertake to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.Contact:WaferGen510-651-4450Don Huffman, CFOdon.huffman@wafergen.comMedia:  Joyce Strandjoyce.strand@wafergen.comInvestors:  Tim Ryantryan@shorehamgroupllc.com212-242-7777WAFERGEN BIOSYSTEMS, INC. AND SUBSIDIARIESCondensed Consolidated Balance SheetsJune 30, 2011December 31, 2010Assets(Unaudited)Current assets:Cash and cash equivalents$

24,668,747$

2,209,941Restricted cash100,826100,651Accounts receivable, net91,007778,769Inventories, net1,134,5081,024,250Prepaid expenses and other current assets100,062176,259Total current assets26,095,1504,289,870Property and equipment, net1,996,8611,191,840Other assets876,351334,855Total assets$

28,968,362$

5,816,565Liabilities and Stockholders' Equity (Deficit)Current liabilities:Accounts payable$

768,946$

1,196,861Accrued payroll and related costs772,810440,101Deferred revenue25,00025,000Other accrued expenses, current portion583,590428,497Current portion of long-term debt2,257419,384Total current liabilities2,152,6032,509,843Other accrued expenses, non-current portion117,293-Long-term debt, net of current portion913,0411,589,468Derivative liability for put option on Series B redeemable convertible preference shares of subsidiary118,476194,088Derivative liability for conversion element of convertible promissory notes13,108,276-Warrant derivative liability1,625,5522,240,962Total liabilities18,035,2416,534,361Series A and B redeemable convertibl
'/>"/>

SOURCE WaferGen Biosystems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. WaferGen to Present at OneMedForum New York 2011
2. WaferGen Closes $30 Million Financing with Three Leading Life Science Institutional Investors
3. WaferGen Announces Data Presentations From Newly Launched High-Throughput SmartChip Human microRNA Panel V2 at Scientific Conferences, Including AACR
4. WaferGen Launches High-Throughput SmartChip Human MicroRNA Panel V2
5. WaferGen Reports Fourth Quarter and Full Year 2010 Financial Results
6. WaferGen Appoints Industry Leader Dr. Timothy J. Triche to Board of Directors
7. WaferGen to Present at 13th Annual BIO CEO and Investor Conference
8. WaferGen Appoints World-Renowned Clinical Genomics Cancer Researcher Dr. Arul M. Chinnaiyan to Scientific Advisory Board
9. WaferGen to Present at OneMedForum San Francisco 2011
10. WaferGen and Integrated BioBank of Luxembourg (IBBL) Sign Strategic Agreement for Molecular Diagnostic Research Collaboration and Purchase of SmartChip System
11. WaferGen Announces $7 Million Capital Raise -- $5 Million Equity Private Placement Agreement Signed, and $2 Million Credit Facility Closed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... Oct. 2, 2014  Perrigo Company plc (NYSE: ... laws of Ireland (the " Company ... (the "Exchange Offer") up to $500,000,000 of its new 1.30% ... $600,000,000 of its new 2.30% Senior Notes due 2018 (the ... Senior Notes due 2023 (the " 2023 Exchange Notes ") ...
(Date:10/2/2014)...   Softworld, Inc. announced today the launch of ... on the specific needs of pharmaceutical, biotech, and medical ... been highly successful in the clinical domain, the team ... the quality, regulatory, and validation space. ... the current Biometric team and the newly created Life ...
(Date:10/2/2014)... , Oct. 2, 2014  Isis Pharmaceuticals, ... following webcast:What: , Webcast and conference call to ... 2 clinical studies of ISIS-SMN Rx in ... which will be presented on the morning (CEST) ... World Muscle Society in Berlin, GermanyWhen:Friday, October 10 ...
Breaking Medicine Technology:Perrigo Company plc Announces Expiration Of Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023, 5.30% Senior Notes Due 2043 2Perrigo Company plc Announces Expiration Of Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023, 5.30% Senior Notes Due 2043 3Perrigo Company plc Announces Expiration Of Exchange Offer For Its 1.30% Senior Notes Due 2016, 2.30% Senior Notes Due 2018, 4.00% Senior Notes Due 2023, 5.30% Senior Notes Due 2043 4Softworld, Inc. Launches Strategic Division Dedicated to Life Sciences Consulting 2Isis Pharmaceuticals to Host Webcast to Discuss ISIS-SMN Rx Results Presented at the World Muscle Society Congress 2
... - Data From Phase 3 Study Presented at ... Wyeth,Pharmaceuticals, a division of Wyeth (NYSE: WYE ... clinical trial that show patients with relapsed,and/or refractory ... treated with the mTOR (mammalian target of rapamycin) ...
... Show 100-Fold More Radiation Delivered to Tumor as Compared ... to Other Organs-, -All Patients ... ... TUSTIN, Calif., May 31 Peregrine,Pharmaceuticals, Inc. (Nasdaq: PPHM ) today reported that ...
Cached Medicine Technology:New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma 2New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma 3New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma 4New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma 5New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma 6Data To Be Presented at ASCO Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer 2Data To Be Presented at ASCO Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer 3Data To Be Presented at ASCO Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer 4Data To Be Presented at ASCO Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer 5
(Date:10/2/2014)... (PRWEB) October 02, 2014 Recently, BambooIndustry.com, ... unveiled its new collection of bamboo floors . ... for a lot of its products at the moment. ... is up to 26 percent off. The promotion will ... bamboo floors ( http://www.bambooindustry.com ) are all made by ...
(Date:10/2/2014)... 02, 2014 Originally considered alternative ... is becoming increasingly popular with consumers. This has ... Poultry Farming industry in Australia. According to ... organic meat has surged over the past five ... the farming level.” Over the five years through ...
(Date:10/2/2014)... have pinpointed a molecule that may trigger potentially life-threatening ... say this finding could offer a target for new ... Most asthma attacks (80 percent to 90 percent) are ... the British researchers. Most of these are rhinoviruses, which ... The researchers found that a specific molecule called IL-25 ...
(Date:10/2/2014)... Dennis Thompson HealthDay Reporter ... of developing celiac disease isn,t reduced by breast-feeding. Nor will ... gluten to an infant,s diet help prevent celiac disease. ... studies in the Oct. 2 New England Journal of ... that a child could avoid celiac disease if mothers breast-feed ...
(Date:10/2/2014)... by scientists at The University of Nottingham could lead ... painkiller. , A drug resulting from the research, published ... offer new hope to sufferers of chronic pain conditions ... painkillers are currently available. , The work, led by ... Sciences, in collaboration with David Bates, Professor of Oncology ...
Breaking Medicine News(10 mins):Health News:BambooIndustry.com: Great Bamboo Floors At Discounted Rates 2Health News:Organic Livestock and Poultry Farming in Australia Industry Market Research Report Now Available from IBISWorld 2Health News:Organic Livestock and Poultry Farming in Australia Industry Market Research Report Now Available from IBISWorld 3Health News:Organic Livestock and Poultry Farming in Australia Industry Market Research Report Now Available from IBISWorld 4Health News:New Clues to How Colds Can Spur Asthma Attacks 2Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 2Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 3Health News:Medical discovery first step on path to new painkillers 2
... high-dose technology targets tumor tissue, experts say , MONDAY, ... doesn,t harm the sexual function of prostate cancer patients, ... Cancer Center in Philadelphia tracked 155 men with intermediate- ... (IMRT), a technique that more precisely targets the tumor. ...
... The implementation of the Physical Agents Directive 2004/40/EC ... diagnosis and treatment Europe wide. Last Fridays publicly ... brakes on a feared future for Magnetic Resonance ... dialogue prior to policy is paramount , ...
... emerging threats to global health and ... diseases, NEW YORK, Oct. 29 The ... achievements in public health. However, the,increased incidence and ... and the re-emergence of tuberculosis, present critical,health challenges ...
... major study published in the November,2007 edition of the ... who completed a study using the Brava System increased,their ... breast size. This key,finding was based on a medical ... M.D. and Alexandra Kaider, M. Sc. The study is ...
... reminder program, TORONTO, Oct. 29 /PRNewswire/ - ... Today! reminder program for its Linessa(R) and,Nuvaring(R) contraceptive ... that helps them remember their contraceptives and,Organon Canada ... and patients. Organon Canada initiated the Remind ...
... of the Achilles tendon can experience a reduction in ... dextrose solution, according to a recent study conducted by ... Chronic tendinosis is a common overuse injury which can ... tendons throughout the body, said Norman J. Maxwell, MD, ...
Cached Medicine News:Health News:Prostate Cancer Radiotherapy Won't Affect Sexual Function 2Health News:Controversial physical agents directive postponed 2Health News:Charlie Rose Science Series to Focus on the Challenge of Researching and Implementing Effective Treatments for Diseases of the Developing World 2Health News:Charlie Rose Science Series to Focus on the Challenge of Researching and Implementing Effective Treatments for Diseases of the Developing World 3Health News:Charlie Rose Science Series to Focus on the Challenge of Researching and Implementing Effective Treatments for Diseases of the Developing World 4Health News:Newly Published Study in Leading Medical Journal Further Confirms the Brava System's Non-Surgical Breast Enhancement Effectiveness 2Health News:Telecommunications Technology Boosts Revenue Generation by Billions and Builds Positive Brand Experience 2Health News:Telecommunications Technology Boosts Revenue Generation by Billions and Builds Positive Brand Experience 3Health News:Ultrasound-guided injections help ease chronic Achilles tendon pain 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: